久久精品欧美日韩精品,中文字幕av区四区三区二区一区,久久久久久精品免费免费麻辣,欧美日韩免费高清大片

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73197KIF5B（E15）-RET（E12） V804E/BaF3

KIF5B（E15）-RET（E12） V804E/BaF3
名稱 KIF5B（E15）-RET（E12） V804E/BaF3
型號 CBP73197
報價
特點 KIF5B（E15）-RET（E12） [V804E]/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73197
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804E]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804E]/BaF3

CBP73197 WB.png


2. Sanger of KIF5B-RET [V804E]/BaF3

CBP73197 sanger1.png

CBP73197 sanger2.png


3. Anti-proliferation assay

CBP73197 fig.jpg


Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804E Cells (C1).




如果你對CBP73197KIF5B（E15）-RET（E12） V804E/BaF3感興趣，想了解更詳細(xì)的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細(xì)地址：

  • 補充說明：

  • 驗證碼：

    請輸入計算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
东北乱国产对白刺激视频| 亚洲国产精品久久久久网站| 婷婷激情网五月天亚洲| 色婷婷久久久久久久久久| 日韩欧美中文字幕一区二区| 国内精品久久久久久久久久久| 欧美日韩一区二区中文字幕| 欧美老熟女多毛茸茸| 国产综合精品久久久久成人蜜臀| 在线电影日韩一区二区三区| 亚洲1区2区3区av| 欧美成人3p视频在线观看| 91久久久久久久国产| 丰满少妇爽视频一区二区三区| 日本一区二区三区免费的视频| 欧美国产日韩精品77上位| 97精品国产综合久久久免费| 日韩在线|中文字幕| 国产精品毛片大码女人| 国产精品日韩主播无套| 最新中文乱码字字幕在线看| 精品国产91乱高清在线观看| 五月婷婷六月丁香免费视频| 人妻精品人妻一区区| 亚洲人妻御姐中文字幕| 9色国产精品一区粉嫩| 青青草原精品国产亚洲av| 99久久无色码中文字幕人妻| 91久久久精品人妻| 日日摸夜夜摸狠狠摸婷婷| 国产精品一区二区三区三级天堂| 欧美综合亚洲日韩精品区| 丰满少妇爽视频一区二区三区| 亚洲欧美一区二区久久| 久久综合视频中文字幕| 久久99精品免费免费| 污污涩涩精品国产网站| 亚洲综合精品欧美日韩一区二区三区91| 草草影院在线免费观看| 欧美日本一道本一区二区三区| 五月婷婷六月丁香综合小说|